Knowledge Graph

Data-synthesized insights that connect scientific claims into a self-reorganizing web of evidence. Each insight is backed by primary studies — not opinion.

GLP-1 receptor agonists reduce cardiovascular mortality and improve metabolic health through mechanisms that are partially independent of weight loss and require direct pharmacological receptor activation, not merely endogenous incretin elevation.

In high-risk patients without prior cardiovascular events, intensive LDL-C lowering below 55 mg/dL significantly reduces major adverse cardiovascular events without increasing safety risks, establishing a new standard for primary and secondary prevention.

Daily low-dose aspirin provides no net clinical benefit in healthy adults aged 70 and older, as the absence of cardiovascular protection is offset by a persistent, dose-independent increase in major hemorrhage risk.